These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23289432)

  • 41. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
    Lankisch MR; Del Prato S; Dain MP; Mullins P; Owens DR
    Prim Care Diabetes; 2016 Feb; 10(1):51-9. PubMed ID: 26150328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017.
    Tan YZ; Cheen MHH; Goh SY; Bee YM; Lim PS; Khee GY; Thumboo J
    J Diabetes; 2019 Jul; 11(7):573-581. PubMed ID: 30556375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
    Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
    Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
    Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
    Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
    Kendall DM; Riddle MC; Rosenstock J; Zhuang D; Kim DD; Fineman MS; Baron AD
    Diabetes Care; 2005 May; 28(5):1083-91. PubMed ID: 15855571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
    Wright A; Burden AC; Paisey RB; Cull CA; Holman RR;
    Diabetes Care; 2002 Feb; 25(2):330-6. PubMed ID: 11815505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
    Vichayanrat A; Matawaran BJ; Wibudi A; Ferdous HS; Aamir AH; Aggarwal SK; Bajpai S
    J Diabetes; 2013 Sep; 5(3):309-18. PubMed ID: 23462227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia.
    Bramlage P; Gitt AK; Binz C; Krekler M; Deeg E; Tschöpe D
    Cardiovasc Diabetol; 2012 Oct; 11():122. PubMed ID: 23039216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
    Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
    Cahn A; Raz I; Mosenzon O; Leibowitz G; Yanuv I; Rozenberg A; Iqbal N; Hirshberg B; Sjostrand M; Stahre C; Im K; Kanevsky E; Scirica BM; Bhatt DL; Braunwald E
    Diabetes Care; 2016 Aug; 39(8):1329-37. PubMed ID: 27222508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study.
    Cigrovski Berković M; Herman Mahečić D; Gradišer M; Bilić-Ćurčić I
    Prim Care Diabetes; 2017 Jun; 11(3):265-272. PubMed ID: 28314484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 55. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia.
    Thorpe CT; Gellad WF; Good CB; Zhang S; Zhao X; Mor M; Fine MJ
    Diabetes Care; 2015 Apr; 38(4):588-95. PubMed ID: 25592195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.
    Lipska KJ; Yao X; Herrin J; McCoy RG; Ross JS; Steinman MA; Inzucchi SE; Gill TM; Krumholz HM; Shah ND
    Diabetes Care; 2017 Apr; 40(4):468-475. PubMed ID: 27659408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
    Shestakova MV; Suhareva OIu; Chernova TO; Shmushkovich IA; Aleksandrov AA; Il'in AV; Dedov II
    Ter Arkh; 2013; 85(8):49-55. PubMed ID: 24137964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes.
    Monami M; Dicembrini I; Kundisova L; Zannoni S; Nreu B; Mannucci E
    Diabetes Obes Metab; 2014 Sep; 16(9):833-40. PubMed ID: 24635837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan.
    Glimepiride in Ramadan (GLIRA) Study Group
    Diabetes Care; 2005 Feb; 28(2):421-2. PubMed ID: 15677804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.